Insmed's Arikayce missed the primary endpoint in a Phase II clinical trial for the treatment of non-tuberculous mycobacterial (NTM) lung infections, but the company emphasized significant results for the trial's secondary endpoint to keep its stock from taking a very steep dive.
Insmed's Arikayce missed the primary endpoint in a Phase II clinical trial for the treatment of non-tuberculous mycobacterial (NTM) lung infections, but the company emphasized significant results for the trial's secondary endpoint to keep its stock from taking a very steep dive.
Monmouth Junction, New Jersey-based Insmed will discuss the data with US and EU regulators to determine the next steps for...
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
